Respiratory syncytial virus infection in adults

Seminars in Respiratory and Critical Care Medicine

Volumn 32, Issue 4, 2011, Pages 423-432

  Walsh, Edward E ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b ROCHESTER GENERAL HOSPITAL   (United States)

Author keywords

palivizumab; Respiratory syncytial virus; respiratory viral infections; RSV

Indexed keywords

BRONCHODILATING AGENT; CD11B ANTIGEN; CHEMOKINE RECEPTOR CX3CR1; CX3C CHEMOKINE; FRACTALKINE; GAMMA INTERFERON; GLUCOCORTICOID; GLYCOPROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LIVE VACCINE; MONOCYTE CHEMOTACTIC PROTEIN 1; MOTAVIZUMAB; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 2; NUCLEOCAPSID PROTEIN; PALIVIZUMAB; RANTES; RIBAVIRIN; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; ADULT; AEROSOL; AGING; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN DETECTION; ANTIVIRAL THERAPY; ARTICLE; BRONCHIOLAR EPITHELIAL CELL; BRONCHIOLITIS; BRONCHIOLITIS OBLITERANS; BRONCHITIS; CD8+ T LYMPHOCYTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COUGHING; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; DIAGNOSTIC PROCEDURE; DISEASE EXACERBATION; DISEASE SEVERITY; DISEASE TRANSMISSION; DYSPNEA; ENDEMIC DISEASE; FLUID THERAPY; FORCED EXPIRATORY VOLUME; GOLD STANDARD; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK INFANT; HOSPITAL PATIENT; HUMAN; HUMAN METAPNEUMOVIRUS; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; IMMUNOPROPHYLAXIS; IN VITRO STUDY; INCIDENCE; INCUBATION TIME; INFECTION RATE; INFLUENZA VACCINATION; INFLUENZA VIRUS; INNATE IMMUNITY; LUNG ALVEOLUS CELL; LUNG TRANSPLANTATION; MACROPHAGE; MORTALITY; NATURAL KILLER CELL; NEUTROPHIL; NOSE CONGESTION; OXYGEN SUPPLY; PARAINFLUENZA VIRUS; PATHOGENESIS; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; REINFECTION; RESPIRATORY FAILURE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SEASONAL VARIATION; SENSITIVITY AND SPECIFICITY; SEROLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; SINUSITIS; STREPTOCOCCUS PNEUMONIAE; T LYMPHOCYTE; TISSUE CULTURE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VIROLOGY; VIRUS LOAD; VIRUS NUCLEOCAPSID; VIRUS SHEDDING; WHEEZING;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; HUMANS; IMMUNOCOMPROMISED HOST; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RIBAVIRIN; UNITED STATES;

EID: 80051960182     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0031-1283282     Document Type: Article

References (121)

1. Blount R E. Jr, Morris J A., Savage R E. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med 1956 92 3 544-549
2. Chanock R, Roizman B, Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg 1957 66 3 281-290
3. Kim H W., Arrobio J O., Brandt C D. et al. Epidemiology of respiratory syncytial virus infection in Washington, D.C., I: Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection. Am J Epidemiol 1973 98 3 216-225
4. Parrott R H., Kim H W., Arrobio J O. et al. Epidemiology of respiratory syncytial virus infection in Washington, D.C., II: Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol 1973 98 4 289-300
5. Brandt C D., Kim H W., Arrobio J O. et al. Epidemiology of respiratory syncytial virus infection in Washington, D.C., III: Composite analysis of eleven consecutive yearly epidemics. Am J Epidemiol 1973 98 5 355-364
6. Nokes D J., Okiro E A., Ngama M et al. Respiratory syncytial virus epidemiology in a birth cohort from Kilifi district, Kenya: infection during the first year of life. J Infect Dis 2004 190 10 1828-1832 (Pubitemid 39487829)
7. Nair H, Nokes D J., Gessner B D. et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010 375 9725 1545-1555
8. Shay D K., Holman R C., Newman R D., Liu L L., Stout J W., Anderson L J. Bronchiolitis-associated hospitalizations among US children, 19801996. JAMA 1999 282 15 1440-1446
9. Zambon M C., Stockton J D., Clewley J P., Fleming D M. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet 2001 358 9291 1410-1416 (Pubitemid 33055743)
10. Falsey A R., Hennessey P A., Formica M A., Cox C, Walsh E E. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005 352 17 1749-1759 (Pubitemid 40570923)
11. Collins P L., Murphy B R. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc Am Thorac Soc 2005 2 2 166-173 (Pubitemid 41233386)
12. Collins P L., Murphy B R. Vaccines against human respiratory syncytial virus. In: Cane P A. ed. Respiratory Syncytial Virus. Amsterdam Elsevier 2007 233
13. Iwane M K., Edwards K M., Szilagyi P G. et al, New Vaccine Surveillance Network. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 2004 113 6 1758-1764 (Pubitemid 38697988)
14. Collins P L., Graham B S. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 2008 82 5 2040-2055 (Pubitemid 351293507)
15. Walsh E E., Schlesinger J J., Brandriss M W. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect Immun 1984 43 2 756-758 (Pubitemid 14176641)
16. Johnson P R., Spriggs M K., Olmsted R A., Collins P L. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci U S A 1987 84 16 5625-5629
17. Collarini E J., Lee F E., Foord O et al. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. J Immunol 2009 183 10 6338-6345
18. Haynes L M., Caidi H, Radu G U. et al. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J Infect Dis 2009 200 3 439-447
19. Harcourt J, Alvarez R, Jones L P., Henderson C, Anderson L J., Tripp R A. Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+T cell responses. J Immunol 2006 176 3 1600-1608 (Pubitemid 43134304)
20. Harcourt J L., Karron R A., Tripp R A. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis. J Infect Dis 2004 190 11 1936-1940 (Pubitemid 39564698)
21. Sullender W M., Mufson M A., Prince G A., Anderson L J., Wertz G W. Antigenic and genetic diversity among the attachment proteins of group A respiratory syncytial viruses that have caused repeat infections in children. J Infect Dis 1998 178 4 925-932 (Pubitemid 28452181)
22. Mufson M A., Belshe R B., Orvell C, Norrby E. Subgroup characteristics of respiratory syncytial virus strains recovered from children with two consecutive infections. J Clin Microbiol 1987 25 8 1535-1539 (Pubitemid 17098736)
23. Hall C B., Walsh E E., Schnabel K C. et al. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J Infect Dis 1990 162 6 1283-1290
24. McConnochie K M., Hall C B., Walsh E E., Roghmann K J. Variation in severity of respiratory syncytial virus infections with subtype. J Pediatr 1990 117 1 Pt 1 52-62 (Pubitemid 20217493)
25. Hall C B., Douglas R G. Jr, Schnabel K C., Geiman J M. Infectivity of respiratory syncytial virus by various routes of inoculation. Infect Immun 1981 33 3 779-783 (Pubitemid 11051070)
26. Lee F E., Walsh E E., Falsey A R. et al. The balance between influenza- and RSV-specific CD4 T cells secreting IL-10 or IFNgamma in young and healthy-elderly subjects. Mech Ageing Dev 2005 126 11 1223-1229 (Pubitemid 41356524)
27. Falsey A R., Treanor J J., Betts R F., Walsh E E. Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J Am Geriatr Soc 1992 40 2 115-119
28. Falsey A R., Formica M A., Treanor J J., Walsh E E. Comparison of quantitative reverse transcription-PCR to viral culture for assessment of respiratory syncytial virus shedding. J Clin Microbiol 2003 41 9 4160-4165 (Pubitemid 37099680)
29. Weinberg G A., Erdman D D., Edwards K M. et al, New Vaccine Surveillance Network Study Group. Superiority of reverse-transcription polymerase chain reaction to conventional viral culture in the diagnosis of acute respiratory tract infections in children. J Infect Dis 2004 189 4 706-710 (Pubitemid 38270925)
30. Subbarao E K., Whitehurst N J., Waner J L. Comparison of two enzyme-linked immunosorbent assay (EIA) kits with immunofluorescence and isolation in cell culture for detection of respiratory syncytial virus (RSV). Diagn Microbiol Infect Dis 1987 8 4 229-234 (Pubitemid 18085828)
31. Ahluwalia G S., Hammond G W. Comparison of cell culture and three enzyme-linked immunosorbent assays for the rapid diagnosis of respiratory syncytial virus from nasopharyngeal aspirate and tracheal secretion specimens. Diagn Microbiol Infect Dis 1988 9 3 187-192
32. Hall W J., Hall C B., Speers D M. Respiratory syncytial virus infection in adults: clinical, virologic, and serial pulmonary function studies. Ann Intern Med 1978 88 2 203-205 (Pubitemid 8282153)
33. Duncan C B., Walsh E E., Peterson D R., Lee F E., Falsey A R. Risk factors for respiratory failure associated with respiratory syncytial virus infection in adults. J Infect Dis 2009 200 8 1242-1246
34. Falsey A R., Formica M A., Walsh E E. Diagnosis of respiratory syncytial virus infection: comparison of reverse transcription-PCR to viral culture and serology in adults with respiratory illness. J Clin Microbiol 2002 40 3 817-820 (Pubitemid 34208629)
35. Englund J A., Piedra P A., Jewell A, Patel K, Baxter B B., Whimbey E. Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults. J Clin Microbiol 1996 34 7 1649-1653 (Pubitemid 26190391)
36. Casiano-Colón A E., Hulbert B B., Mayer T K., Walsh E E., Falsey A R. Lack of sensitivity of rapid antigen tests for the diagnosis of respiratory syncytial virus infection in adults. J Clin Virol 2003 28 2 169-174 (Pubitemid 37040869)
37. Walsh E E., Falsey A R. Age related differences in humoral immune response to respiratory syncytial virus infection in adults. J Med Virol 2004 73 2 295-299 (Pubitemid 38542686)
38. Hall C B., Kopelman A E., Douglas R G. Jr, Geiman J M., Meagher M P. Neonatal respiratory syncytial virus infection. N Engl J Med 1979 300 8 393-396 (Pubitemid 9134284)
39. Nicholson K G., Kent J, Hammersley V, Cancio E. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. BMJ 1997 315 7115 1060-1064 (Pubitemid 27458400)
40. Nicholson K G. Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990. Epidemiol Infect 1996 116 1 51-63 (Pubitemid 26112441)
41. Griffin M R., Coffey C S., Neuzil K M., Mitchel E F. Jr, Wright P F., Edwards K M. Winter viruses: influenza- and respiratory syncytial virus-related morbidity in chronic lung disease. Arch Intern Med 2002 162 11 1229-1236 (Pubitemid 34595028)
42. Mullooly J P., Bridges C B., Thompson W W. et al, Vaccine Safety Datalink Adult Working Group. Influenza- and RSV-associated hospitalizations among adults. Vaccine 2007 25 5 846-855 (Pubitemid 44873160)
43. Thompson W W., Shay D K., Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003 289 2 179-186 (Pubitemid 36068705)
44. Hall C B., Long C E., Schnabel K C. Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis 2001 33 6 792-796 (Pubitemid 32831835)
45. Hall W J., Hall C B., Speers D M. Respiratory syncytial virus infection in adults: clinical, virologic, and serial pulmonary function studies. Ann Intern Med 1978 88 2 203-205 (Pubitemid 8282153)
46. Falsey A R., Cunningham C K., Barker W H. et al. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J Infect Dis 1995 172 2 389-394
47. Hutchinson A F., Ghimire A K., Thompson M A. et al. A community-based, time-matched, case-control study of respiratory viruses and exacerbations of COPD. Respir Med 2007 101 12 2472-2481 (Pubitemid 47618387)
48. De Serres G, Lampron N, La Forge J et al. Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations. J Clin Virol 2009 46 2 129-133
49. Camargo C A. Jr, Ginde A A., Clark S, Cartwright C P., Falsey A R., Niewoehner D E. Viral pathogens in acute exacerbations of chronic obstructive pulmonary disease. Intern Emerg Med 2008 3 4 355-359
50. Ko F W., Ip M, Chan P K. et al. Viral etiology of acute exacerbations of COPD in Hong Kong. Chest 2007 132 3 900-908
51. Beckham J D., Cadena A, Lin J et al. Respiratory viral infections in patients with chronic, obstructive pulmonary disease. J Infect 2005 50 4 322-330 (Pubitemid 40533369)
52. Rohde G, Wiethege A, Borg I et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax 2003 58 1 37-42 (Pubitemid 36135356)
53. Falsey A R., Formica M A., Hennessey P A., Criddle M M., Sullender W M., Walsh E E. Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006 173 6 639-643 (Pubitemid 43363805)
54. Wilkinson T M., Donaldson G C., Johnston S L., Openshaw P J., Wedzicha J A. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006 173 8 871-876
55. Sikkel M B., Quint J K., Mallia P, Wedzicha J A., Johnston S L. Respiratory syncytial virus persistence in chronic obstructive pulmonary disease. Pediatr Infect Dis J 2008 27 10, Suppl S63-S70
56. Borg I, Rohde G, Löseke S et al. Evaluation of a quantitative real-time PCR for the detection of respiratory syncytial virus in pulmonary diseases. Eur Respir J 2003 21 6 944-951 (Pubitemid 36675608)
57. Nicholson K G., McNally T, Silverman M, Simons P, Stockton J D., Zambon M C. Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children. Vaccine 2006 24 1 102-108 (Pubitemid 41721106)
58. Dowell S F., Anderson L J., Gary H E. Jr et al. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J Infect Dis 1996 174 3 456-462 (Pubitemid 26299676)
59. Walsh E E., Peterson D R., Falsey A R. Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible? J Infect Dis 2007 195 7 1046-1051 (Pubitemid 46452111)
60. DeVincenzo J P., Wilkinson T, Vaishnaw A et al. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 2010 182 10 1305-1314
61. DeVincenzo J P., El Saleeby C M., Bush A J. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis 2005 191 11 1861-1868 (Pubitemid 40705393)
62. Buckingham S C., Bush A J., Devincenzo J P. Nasal quantity of respiratory syncytial virus correlates with disease severity in hospitalized infants. Pediatr Infect Dis J 2000 19 2 113-117 (Pubitemid 30111405)
63. Houben M L., Coenjaerts F E., Rossen J W. et al. Disease severity and viral load are correlated in infants with primary respiratory syncytial virus infection in the community. J Med Virol 2010 82 7 1266-1271
64. Walsh E E., Peterson D R., Falsey A R. Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis 2004 189 2 233-238 (Pubitemid 38147246)
65. Falsey A R. Noninfluenza respiratory virus infection in long-term care facilities. Infect Control Hosp Epidemiol 1991 12 10 602-608
66. Mathur U, Bentley D W., Hall C B. Concurrent respiratory syncytial virus and influenza A infections in the institutionalized elderly and chronically ill. Ann Intern Med 1980 93 1 49-52 (Pubitemid 10072002)
67. Caram L B., Chen J, Taggart E W. et al. Respiratory syncytial virus outbreak in a long-term care facility detected using reverse transcriptase polymerase chain reaction: an argument for real-time detection methods. J Am Geriatr Soc 2009 57 3 482-485
68. Drinka P J., Gravenstein S, Krause P et al. Non-influenza respiratory viruses may overlap and obscure influenza activity. J Am Geriatr Soc 1999 47 9 1087-1093 (Pubitemid 29420615)
69. Ellis S E., Coffey C S., Mitchel E F. Jr, Dittus R S., Griffin M R. Influenza- and respiratory syncytial virus-associated morbidity and mortality in the nursing home population. J Am Geriatr Soc 2003 51 6 761-767 (Pubitemid 36693424)
70. Falsey A R., McCann R M., Hall W J. et al. Acute respiratory tract infection in daycare centers for older persons. J Am Geriatr Soc 1995 43 1 30-36
71. Wendt C H., Hertz M I. Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host. Semin Respir Infect 1995 10 4 224-231 (Pubitemid 26007454)
72. McColl M D., Corser R B., Bremner J, Chopra R. Respiratory syncytial virus infection in adult BMT recipients: effective therapy with short duration nebulised ribavirin. Bone Marrow Transplant 1998 21 4 423-425 (Pubitemid 28080482)
73. Mazzulli T, Peret T C., McGeer A et al. Molecular characterization of a nosocomial outbreak of human respiratory syncytial virus on an adult leukemia/lymphoma ward. J Infect Dis 1999 180 5 1686-1689 (Pubitemid 29506475)
74. Whimbey E, Champlin R E., Couch R B. et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996 22 5 778-782 (Pubitemid 26255593)
75. Whimbey E, Couch R B., Englund J A. et al. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis 1995 21 2 376-379
76. Englund J A., Anderson L J., Rhame F S. Nosocomial transmission of respiratory syncytial virus in immunocompromised adults. J Clin Microbiol 1991 29 1 115-119
77. Hertz M I., Englund J A., Snover D, Bitterman P B., McGlave P B. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature. Medicine (Baltimore) 1989 68 5 269-281 (Pubitemid 19251931)
78. Englund J A., Sullivan C J., Jordan M C., Dehner L P., Vercellotti G M., Balfour H H. Jr. Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med 1988 109 3 203-208
79. Shah J N., Chemaly R F. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011 117 10 2755-2763
80. Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haematol 2008 143 4 455-467
81. Erard V, Chien J W., Kim H W. et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis 2006 193 12 1619-1625 (Pubitemid 43839464)
82. Kim Y J., Boeckh M, Englund J A. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin Respir Crit Care Med 2007 28 2 222-242 (Pubitemid 46676916)
83. Zamora M R., Budev M, Rolfe M et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 2011 183 4 531-538
84. Kumar D, Erdman D, Keshavjee S et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant 2005 5 8 2031-2036 (Pubitemid 41039882)
85. Glezen W P., Paredes A, Allison J E., Taber L H., Frank A L. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981 98 5 708-715 (Pubitemid 11070320)
86. Carbonell-Estrany X, Simões E A., Dagan R et al, Motavizumab Study Group. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 2010 125 1 e35-e51
87. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998 102 3 531-537
88. Malley R, DeVincenzo J, Ramilo O et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis 1998 178 6 1555-1561 (Pubitemid 28558122)
89. Lee F E., Walsh E E., Falsey A R., Betts R F., Treanor J J. Experimental infection of humans with A2 respiratory syncytial virus. Antiviral Res 2004 63 3 191-196 (Pubitemid 39286756)
90. Mills J V., Van Kirk J E., Wright P F., Chanock R M. Experimental respiratory syncytial virus infection of adults: possible mechanisms of resistance to infection and illness. J Immunol 1971 107 1 123-130
91. Hall C B., Walsh E E., Long C E., Schnabel K C. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991 163 4 693-698
92. Walsh E E., Falsey A R. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis 2004 190 2 373-378 (Pubitemid 38951980)
93. Martinez-Sobrido L, Gitiban N, Fernandez-Sesma A et al. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J Virol 2006 80 3 1130-1139 (Pubitemid 43134070)
94. Johnson T R., Mertz S E., Gitiban N et al. Role for innate IFNs in determining respiratory syncytial virus immunopathology. J Immunol 2005 174 11 7234-7241 (Pubitemid 40705692)
95. Villenave R, O'Donoghue D, Thavagnanam S et al. Differential cytopathogenesis of respiratory syncytial virus prototypic and clinical isolates in primary pediatric bronchial epithelial cells. Virol J 2011 8 1 43
96. Thornburg N J., Shepherd B, Crowe J E. Jr. Transforming growth factor beta is a major regulator of human neonatal immune responses following respiratory syncytial virus infection. J Virol 2010 84 24 12895-12902
97. Oshansky C M., Barber J P., Crabtree J, Tripp R A. Respiratory syncytial virus F and G proteins induce interleukin 1alpha, CC, and CXC chemokine responses by normal human bronchoepithelial cells. J Infect Dis 2010 201 8 1201-1207
98. Oshansky C M., Zhang W, Moore E, Tripp R A. The host response and molecular pathogenesis associated with respiratory syncytial virus infection. Future Microbiol 2009 4 3 279-297
99. Halfhide C P., Brearey S P., Flanagan B F. et al. Neutrophil TLR4 expression is reduced in the airways of infants with severe bronchiolitis. Thorax 2009 64 9 798-805
100. Lukens M V., van de Pol A C., Coenjaerts F E. et al. A systemic neutrophil response precedes robust CD8(+) T-cell activation during natural respiratory syncytial virus infection in infants. J Virol 2010 84 5 2374-2383
101. Miyairi I, DeVincenzo J P. Human genetic factors and respiratory syncytial virus disease severity. Clin Microbiol Rev 2008 21 4 686-703
102. Janssen R, Bont L, Siezen C L. et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes. J Infect Dis 2007 196 6 826-834 (Pubitemid 47378931)
103. Kapikian A Z., Mitchell R H., Chanock R M., Shvedoff R A., Stewart C E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969 89 4 405-421
104. Lee D C., Harker J A., Tregoning J S. et al. CD25+natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection. J Virol 2010 84 17 8790-8798
105. Welliver T P., Reed J L., Welliver R CS Sr. Respiratory syncytial virus and influenza virus infections: observations from tissues of fatal infant cases. Pediatr Infect Dis J 2008 27 10, Suppl S92-S96
106. Welliver T P., Garofalo R P., Hosakote Y et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 2007 195 8 1126-1136 (Pubitemid 46543443)
107. Looney R J., Falsey A R., Walsh E, Campbell D. Effect of aging on cytokine production in response to respiratory syncytial virus infection. J Infect Dis 2002 185 5 682-685 (Pubitemid 34171474)
108. Groothuis J R., Woodin K A., Katz R et al. Early ribavirin treatment of respiratory syncytial viral infection in high-risk children. J Pediatr 1990 117 5 792-798 (Pubitemid 20382621)
109. Hall C B., McBride J T., Gala C L., Hildreth S W., Schnabel K C. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease. JAMA 1985 254 21 3047-3051 (Pubitemid 16139275)
110. Englund J A., Piedra P A., Jefferson L S., Wilson S Z., Taber L H., Gilbert B E. High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. J Pediatr 1990 117 2 Pt 1 313-320 (Pubitemid 20238553)
111. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics 2006 118 4 1774-1793
112. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997 99 1 93-99
113. Zempsky W T., Schechter N L. IMpact-RSV study group report. Pediatrics 1999 104 4 Pt 1 993-994 author reply 995
114. Lee F E., Walsh E E., Falsey A R. The effect of steroid use in hospitalized adults with respiratory syncytial virus related illness. Chest 2011 May 12. [Epub ahead of print]
115. Chemaly R F., Ghosh S, Bodey G P. et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006 85 5 278-287 (Pubitemid 44401460)
116. Torres H A., Aguilera E A., Mattiuzzi G N. et al. Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia. Haematologica 2007 92 9 1216-1223 (Pubitemid 350144180)
117. Empey K M., Peebles R S. Jr, Kolls J K. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis 2010 50 9 1258-1267
118. Murata Y. Respiratory syncytial virus vaccine development. Clin Lab Med 2009 29 4 725-739
119. Gonzalez I M., Karron R A., Eichelberger M et al. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine 2000 18 17 1763-1772 (Pubitemid 30122838)
120. Falsey A R., Walsh E E., Capellan J et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccinesnonadjuvanted vaccine or vaccine adjuvanted with alumgiven concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis 2008 198 9 1317-1326
121. Falsey A R., Walsh E E. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine 1996 14 13 1214-1218 (Pubitemid 26388731)